Lisata Therapeutics, Inc. (LSTA)

Market Cap	24.93M
Revenue (ttm)	1,000,000
Net Income (ttm)	-19.31M
Shares Out	8.60M
EPS (ttm)	-2.30
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	99,801
Open	2.525
Previous Close	2.480
Day's Range	2.525 - 3.000
52-Week Range	1.870 - 4.200
Beta	1.03
Analysts	Strong Buy
Price Target	15.00 (+417.24%)
Earnings Date	Aug 11, 2025

About LSTA

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with a range of anti-cancer regimens. The company was incorporated in 1980 and is hea...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1980
• Employees: 26
• Stock Exchange: NASDAQ
• Ticker Symbol: LSTA
• Website: https://www.lisata.com

Analyst Summary

According to one analyst, the rating for LSTA stock is "Strong Buy" and the 12-month stock price target is $15.0.

Price Target

$15.0

(417.24% upside)

Analyst Consensus: Strong Buy